Skip to main content

A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.

Publication ,  Journal Article
Grilley-Olson, JE; Keedy, VL; Sandler, A; Moore, DT; Socinski, MA; Stinchcombe, TE
Published in: Oncologist
February 2015

BACKGROUND: Platinum plus etoposide is the standard therapy for extensive-stage small cell lung cancer (ES-SCLC) and is associated with significant myelosuppression. We hypothesized that the combination of carboplatin and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) would be better tolerated. We investigated carboplatin with nab-paclitaxel on every-3-week and weekly schedules. METHODS: This noncomparative randomized phase II trial used a two-stage design. The primary objective was objective response rate, and secondary objectives were progression-free survival, overall survival, and toxicity. Patients with ES-SCLC and an Eastern Cooperative Oncology Group performance status ≤2 and no prior chemotherapy were randomized in a 1:1 ratio to arm A (carboplatin area under the curve [AUC] of 6 on day 1 and nab-paclitaxel of 300 mg/m(2) on day 1 every 3 weeks) or arm B (carboplatin AUC of 6 on day 1 and nab-paclitaxel 100 mg/m(2) on days 1, 8, and 15 every 21 days). Response was assessed after every two cycles. RESULTS: Patients required frequent dose reductions, treatment delays, and omission of the weekly therapy. The trial was closed because of slow accrual. CONCLUSION: Carboplatin and nab-paclitaxel demonstrated activity in ES-SCLC but required frequent dose adjustments.

Duke Scholars

Published In

Oncologist

DOI

EISSN

1549-490X

Publication Date

February 2015

Volume

20

Issue

2

Start / End Page

105 / 106

Location

England

Related Subject Headings

  • Treatment Outcome
  • Small Cell Lung Carcinoma
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Nanoparticles
  • Middle Aged
  • Male
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Grilley-Olson, J. E., Keedy, V. L., Sandler, A., Moore, D. T., Socinski, M. A., & Stinchcombe, T. E. (2015). A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. Oncologist, 20(2), 105–106. https://doi.org/10.1634/theoncologist.2014-0327
Grilley-Olson, Juneko E., Vicki L. Keedy, Alan Sandler, Dominic T. Moore, Mark A. Socinski, and Thomas E. Stinchcombe. “A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.Oncologist 20, no. 2 (February 2015): 105–6. https://doi.org/10.1634/theoncologist.2014-0327.
Grilley-Olson, Juneko E., et al. “A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.Oncologist, vol. 20, no. 2, Feb. 2015, pp. 105–06. Pubmed, doi:10.1634/theoncologist.2014-0327.

Published In

Oncologist

DOI

EISSN

1549-490X

Publication Date

February 2015

Volume

20

Issue

2

Start / End Page

105 / 106

Location

England

Related Subject Headings

  • Treatment Outcome
  • Small Cell Lung Carcinoma
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Nanoparticles
  • Middle Aged
  • Male
  • Humans
  • Female